Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart PK and CYP Substrates in Ulcerative Colitis
NCT07665723Phase 1Recruiting
- Sponsor
- Roche
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of afimkibart in ulcerative colitis (UC), sponsored by Roche. Primary endpoints: Area Under the Plasma Concentration-time Curve Up to Time t at 13 weeks, Area Under the Plasma Concentration-time Curve Extrapolated to Infinity at 13 weeks and 6 more. Started Jun 2026; status: recruiting.
02
Drugs
afimkibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07665723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07665723.